MK-5204: An orally active β-1,3-glucan synthesis inhibitor.

[1]  T. Walsh,et al.  Drugs currently under investigation for the treatment of invasive candidiasis , 2017, Expert opinion on investigational drugs.

[2]  P. Liberator,et al.  Novel orally active inhibitors of β-1,3-glucan synthesis derived from enfumafungin. , 2015, Bioorganic & medicinal chemistry letters.

[3]  M. Arendrup,et al.  Echinocandin resistance: an emerging clinical problem? , 2014, Current opinion in infectious diseases.

[4]  B. Moriyama,et al.  Emerging drugs and vaccines for Candidemia , 2014, Mycoses.

[5]  K. Kerl,et al.  Invasive candidiasis: update on current pharmacotherapy options and future perspectives , 2013, Expert opinion on pharmacotherapy.

[6]  D. Perlin.  Current perspectives on echinocandin class drugs. , 2011, Future microbiology.

[7]  D. Denning,et al.  Therapy for fungal diseases: opportunities and priorities. , 2010, Trends in microbiology.

[8]  Ana Espinel-Ingroff,et al.  Antifungal drug resistance mechanisms , 2009, Expert review of anti-infective therapy.

[9]  M. Pfaller,et al.  Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem , 2007, Clinical Microbiology Reviews.

[10]  N. Cosford,et al.  Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. , 2004, Journal of medicinal chemistry.

[11]  N. Wiederhold,et al.  The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy , 2003, Expert opinion on investigational drugs.

[12]  N. Gow,et al.  Antifungal agents: mechanisms of action. , 2003, Trends in microbiology.

[13]  S. Volkman,et al.  Asymmetric synthesis of protected 1,2-amino alcohols using tert-butanesulfinyl aldimines and ketimines. , 2001, The Journal of organic chemistry.

[14]  Scott K. Smith,et al.  Isolation and Structural Determination of Enfumafungin, a Triterpene Glycoside Antifungal Agent That Is a Specific Inhibitor of Glucan Synthesis , 2000 .

[15]  R. Schwartz,et al.  Discovery of Novel Antifungal (1,3)-β-d-Glucan Synthase Inhibitors , 2000, Antimicrobial Agents and Chemotherapy.

[16]  J. Smith,et al.  Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis , 1997, Antimicrobial agents and chemotherapy.

[17]  D. Schmatz,et al.  In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin , 1992, Antimicrobial Agents and Chemotherapy.

[18]  B. Kullberg,et al.  Invasive Candidiasis. , 2015, The New England journal of medicine.

[19]  M. Pfaller,et al.  Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. , 2012, The American journal of medicine.